Miro.qxp 31/7/08 10:36 am Page 94
Bacterial Infections
JM, Moreno A, del Río A, Cervera C, Gatell JM (Infectious Diseases JL, Azqueta M, Sitges M, Paré JC, Sanz G (Cardiovascular Institute); Pérez
Service); Marco F, García de la Mària C, Armero Y, Almela M, Jiménez de N, Ramírez J, Ribalta T (Pathology Department); Brunet M (Toxicology
Anta MT (Microbiology Service); Mestres CA, Cartañá R, Ninot S, Pomar Service); Soy D (Pharmacy Service); and de Lazzari E (UASP).
1. Miró JM, Anguera I, Cabell CH, et al.; International Collaboration endocarditis, Antimicrob Agents Chemother, 2000;44:3022–7. Chemother, 2000;45:315–20.
on Endocarditis Merged Database Study Group, Staphylococcus 25. Gutschik E, Christensen N, Experimental endocarditis in rabbits. 2. 46. Martínez-Lacasa J, Cabellos C, Martos A, et al., Experimental
aureus native valve infective endocarditis: report of 566 episodes Course of untreated Streptococcus faecalis infection, Acta Pathol study of the efficacy of vancomycin, rifampicin and
from the International Collaboration on Endocarditis Merged Microbiol Scand B, 1978;86:223–8. dexamethasone in the therapy of pneumococcal meningitis,
Database, Clin Infect Dis, 2005;41(4):507–14. 26. Overholser CD, Moreillon P, Glauser MP, Experimental J Antimicrob Chemother, 2002;49:507–13.
2. Lew DP, Waldvogel FA, Osteomyelitis, N Engl J Med, 1997;336: endocarditis following dental extractions in rats with periodontitis, 47. Ribes S, Taberner F, Domenech A, et al., Evaluation of ceftriaxone,
999–1007. J Oral Maxillofac Surg, 1989;46:857–61. vancomycin and rifampin alone and combined in an experimental
3. Lobati F, Herndon B, Bamberger D, Osteomyelitis: etiology, 27. Malinverni R, Overholser CD, Bille J, et al., Antibiotic prophylaxis model of meningitis caused by highly cephalosporin-resistant
diagnosis, treatment and outcome in a public versus a private of experimental endocarditis after dental extractionsm, Circulation, Streptococcus pneumoniae ATCC 51916, J Antimicrob Chemother,
institution, Infection, 2001;29:333–6. 1988;77:182–7. 2005;56:979–82.
4. Benfield T, Espersen F, Frimodt-Moller N, et al., Increasing 28. Rouse MS, Steckelberg JM, Brandt CM, et al., Efficacy of 48. Esposito AL, Pennington JE, Effects of aging on antibacterial
incidence but decreasing in-hospital mortality of adult azithromycin or clarithromycin for prophylaxis of viridans group mechanisms in experimental pneumonia, Am Rev Respir Dis,
Staphylococcus aureus bacteraemia between 1981 and 2000, streptococcus experimental endocarditis, Antimicrob Agents 1983;128:662–7.
Clin Microbiol Infect, 2007;13:257–63. Chemother, 1997;41(8):1673–6. 49. Rodríguez-Hernández MJ, Pachón J, Pichardo C, et al., Imipenem,
5. Mathews CJ, Kingsley G, Field M, et al., Management of septic 29. Dajani AS, Taubert KA, Wilson W, et al., Prevention of bacterial doxycycline and amikacin in monotherapy and in combination in
arthritis: a systematic review, Ann Rheum Dis, 2007;66(4):440–45. endocarditis: recommendations by the American Heart Acinetobacter baumannii experimental pneumonia, J Antimicrob
6. Chambers HF, The changing epidemiology of Staphylococcus Association, Clin Infect Dis, 1997;25(6):1448–58. Chemother, 2000;45:493–501.
aureus?, Emerg Infect Dis, 2001;7:178–82. 30. Levine DP, Fromm BS, Reddy BR, Slow response to vancomycin or 50. Bernabeu-Wittel M, Pichardo C, García-Curiel A, et al.,
7. Styers D, Sheehan DJ, Hogan P, et al., Laboratory-based vancomycin plus rifampin in methicillin-resistant Staphylococcus Pharmacokinetic/ pharmacodynamic assessment of the in vivo
surveillance of current antimicrobial resistance patterns and trends aureus endocarditis, Ann Intern Med, 1991;115:674–80. efficacy of imipenem alone or in combination with amikacin for
among Staphylococcus aureus: 2005 status in the United States, 31. Cunha BA, Methicillin-resistant Staphylococcus aureus: clinical the treatment of experimental multiresistant Acinetobacter
Ann Clin Microbiol Antimicrob, 2006;5:2. manifestations and antimicrobial therapy, Clin Microbiol Infect, baumannii pneumonia, Clin Microbiol Infect, 2005;11:319–25.
8. Levine DP, Vancomycin: a history, Clin Infect Dis, 2006;42 2005;11(Suppl. 4):33–42. 51. Pachón-Ibáñez ME, Fernández-Cuenca F, Docobo-Pérez F, et al.,
(Suppl. 1):S5–12. 32. Tenover FC, Biddle JW, Lancaster MV, Increasing resistance to Prevention of rifampicin resistance in Acinetobacter baumannii in
9. Stevens DL, The role of vancomycin in the treatment paradigm, vancomycin and other glycopeptides in Staphylococcus aureus, an experimental pneumonia murine model, using rifampicin
Clin Infect Dis, 2006;42(Suppl. 1):S51–7. Emerg Infect Dis, 2001;7:327–32. associated with imipenem or sulbactam, J Antimicrob Chemother,
10. Ruef C, Epidemiology and clinical impact of glycopeptide 33. Voorn GP, Kuyvenhoven J, Goessens WH, et al., Role of tolerance 2006;58(3):689–92.
resistance in Staphylococcus aureus, Infection, 2004;32:315–27. in treatment and prophylaxis of experimental Staphylococcus 52. Costerton JW, Stewart PS, Greenberg EP, Bacterial biofilms: a
11. Pfeltz RF, Wilkinson BJ, The escalating challenge of vancomycin aureus endocarditis with vancomycin, teicoplanin, and common cause of persistent infections, Science, 1999;284:
resistance in Staphylococcus aureus, Curr Drug Targets Infect daptomycin, Antimicrob Agents Chemother, 1994;38:487–93. 1318–22.
Disord, 2004;4:273–94. 34. Miró JM, García-de-la-Mària C, Armero Y, et al.; The Hospital 53. Gristina AG, Biomaterial-centered infection: microbial adhesion
12. Fridkin SK, Hageman J, McDougal LK, et al.; Vancomycin- Clínic Experimental Endocarditis Study Group, Efficacy of versus tissue integration, Science, 1987;237:1588–95.
Intermediate Staphylococcus aureus Epidemiology Study Group, telavancin in the treatment of experimental endocarditis due to 54. Dankert J, Hogt A, Feijen J, Biomedical polymers: bacterial
Epidemiological and microbiological characterization of infections glycopeptide-intermediate Staphylococcus aureus, Antimcrob adhesion, colonization, and infection, CRC Crit Rev Biocompat,
caused by Staphylococcus aureus with reduced susceptibility to Agents Chemother, 2007;51:2373–7. 1986;2:219–301.
vancomycin, United States, 1997–2001, Clin Infect Dis, 35. Marco F, de la Mària CG, Armero Y, et al.; Hospital Clinic 55. Seifert H, Jansen B, Farr B, Catheter-related infections, New York,
2003;36:429–39. Experimental Endocarditis Study Group, Daptomycin is effective in NY: Marcel Dekker Press, 1997.
13. Fowler VG Jr, Miro JM, Hoen B, et al.; ICE Investigators, treatment of experimental endocarditis due to methicillin-resistant 56. Waldvogel FA, Bisno AL, Infections associated with indwelling
Staphylococcus aureus endocarditis: a consequence of medical and glycopeptide-intermediate Staphylococcus aureus, Antimicrob medical devices, Washington, DC: ASM Press, 2000.
progress, JAMA, 2005;293:3012–21. Agents Chemother, 2008;52:2538–43. 57. Gotz F, Heilmann C, Cramton SE, Molecular basis of catheter
14. Clawson CC, White JG, Platelet interaction with bacteria. I. 36. Mainardi JL, Gutmann L, Acar J, Goldstein F, Synergistic effect of associated infections by staphylococci, Adv Exp Med Biol,
Reaction phases and effects of inhibitors, Am J Pathol, amoxicillin and cefotaxime against Enterococcus faecalis, 2000;485:103–11.
1971;82:367–80. Antimicrob Agent Chemother, 1995;39:1984–7. 58. Costerton JW, Cheng KJ, Geesey GG, et al., Bacterial biofilms in
15. Kurpiewski GE, Forrester LE, Campbell BJ, et al., Platelet 37. Gavaldá J, Torres C, Tenorio C, et al., Efficacy of ampicillin plus nature and disease, Annu Rev Microbiol, 1987;41:435–64.
aggregation by Streptococcus pyogenes, Infect Immun, ceftriaxone in treatment of experimental endocarditis due to 59. Gander S, Kinnaird A, Finch R, Telavancin: in vitro activity against
1983;39:704–8. Enterococcus faecalis strains highly resistant to aminoglycosides, staphylococci in a biofilm model, J Antimicrob Chemother,
16. Sullam PM, Valone FH, Mills J, Mechanisms of platelet Antimicrob Agent Chemother, 1999;43:639–46. 2005;56:337–43.
aggregation by viridans group streptococci, Infect Immun, 38. Gavaldá J, Len O, Miró JM, et al., Treatment of Enteroccus faecalis 60. Raad I, Hanna H, Jiang Y, et al. Comparative activities of
1987;55(8):1743–50. endocarditis with ampicillin plus ceftriaxone, Ann Intern Med, daptomycin, linezolid, and tigecycline against catheter-related
17. Zak O, Sande M (eds), Handbook of animal models of infection, 2007;146:574–9. methicillin-resistant Staphylococcus bacteremic isolates embedded
London, UK: Academic Press, 1999. 39. Dacey MG, Sande MA, Effect of probenecid on cerebrospinal fluid in biofilm, Antimicrob Agents Chemother, 2007;51(5):1656–60.
18. Gavaldà J, Cardona PJ, Almirante B, et al., Treatment of concentrations of penicillin and cephalosporin derivates, 61. Kwakman PHS, Velde AA, Vandenbroucke-Grauls CMJE, et al.,
experimental endocarditis due to Enterococcus faecalis using once Antimicrobial Agents Chemother, 1974;57:437–41. Treatment and Prevention of Staphylococcus epidermidis
daily dosing regimen of gentamicin plus simulated profiles of 40. Winter AJ, Marwick S, Osborne M, et al., Ultrastructural damage Experimental Biomaterial-Associated Infection by Bactericidal
ampicillin in human serum, Antimicrob Agents Chemother, to the organ of corti during acute experimental Escherichia coli Peptide 2, Antimicrob Agents Chemother, 2006;50:3977–83.
1996;40:173–8. and pneumococcal meningitis in guinea pigs, Acta Otolaryngol, 62. Lucet JC, Herrmann M, Rohner P, et al., Treatment of experimental
19. Moreillon P, Que YA, Infective endocarditis, Lancet, 2004;363: 1996;116:401–7. foreign body infection caused by methicillin-resistant Staphylococcus
139–49. 41. Liu CT, Guo ZM, Technique for repeated collection of aureus, Antimicrob Agents Chemother, 1990;34:2312–17.
20. Millar BC, Moore JE, Emerging issues in infective endocarditis, cerebrospinal fluid from cisterna magna of anesthetized strain 13 63. Schaad HJ, Chuard C, Vaudaux P, et al., Comparative efficacies of
Emerg Infect Dis, 2004;10:1110–16. guinea pigs, Proc Soc Exp Biol Med, 1991;197:400–403. imipenem, oxacillin and vancomycin for therapy of chronic foreign
21. Sanabria TJ, Alpert JS, Goldberg R, et al., Increasing frequency of 42. Maiques JM, Doménech A, Cabellos C, et al., Evaluation of body infection due to methicillin- susceptible and -resistant
staphylococcal infective endocarditis. Experience at a university antimicrobial regimens in a guinea-pig model of meningitis caused Staphylococcus aureus, J Antimicrob Chemother,
hospital, 1981 through 1988, Arch Intern Med, 1990;150:1305–9. by Pseudomonas aeruginosa, Microbes Infect, 2007;9:435–41. 1994;33:1191–1200.
22. Garrison PK, Freedman LR, Experimental endocarditis. I. 43. Martos A, Cabellos C, Martínez-Lacasa J, et al., Protective effect 64. Vaudaux P, Francois P, Bisognano C, et al., Comparison of
Staphylococcal endocarditis in rabbits resulting from placement of of dexamethasone and phenytoin in the treatment of experimental levofloxacin, alatrofloxacin, and vancomycin for prophylaxis and
a polyethylene catheter in right side of the heart, Yale J Biol Med, pneumococcal meningitis, Enferm Infecc Microbiol Clin, 1995;13: treatment of experimental foreign-bodyassociated infection by
1970;42:394–410. 146–50. methicillin-resistant Staphylococcus aureus, Antimicrob Agents
23. Entenza JM, Que YA, Vouillamoz J, et al., Efficacies of 44. Viladrich P, Cabellos C, Pallares R, et al., High doses of cefotaxime Chemother, 2002;46:1503–9.
moxifloxacin, ciprofloxacin, and vancomycin against experimental in treatment of adult meningitis due to Streptococcus pneumoniae 65. Vaudaux P, Francois P, Bisognano C, et al., Comparative efficacy
endocarditis due to methicillin-resistant Staphylococcus aureus with decreased susceptibilities to broad-spectrum cephalosporins, of daptomycin and vancomycin in the therapy of experimental
expressing various degrees of ciprofl oxacin resistance, Antimicrob Antimicrob Agent Chemother, 1996;40:218–20. foreign body infection due to Staphylococcus aureus, J Antimicrob
Agents Chemother, 2001,45:3076–83. 45. Cabellos C, Martínez-Lacasa J, Tubau F, et al., Evaluation of Chemother, 2003;52:89–95.
24. Murphy TM, Deitz JM, Petersen PJ, et al., Therapeutic efficacy of combined ceftriaxone and dexamethasone therapy in experimental
GAR-936, a novel glycylcycline, in a rat model of experimental cephalosporin-resistant pneumococcal meningitis, J Antimicrob
94 EUROPEAN INFECTIOUS DISEASE
Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92  |  Page 93  |  Page 94  |  Page 95  |  Page 96  |  Page 97  |  Page 98  |  Page 99  |  Page 100  |  Page 101  |  Page 102  |  Page 103  |  Page 104  |  Page 105  |  Page 106  |  Page 107  |  Page 108  |  Page 109  |  Page 110  |  Page 111  |  Page 112  |  Page 113  |  Page 114  |  Page 115  |  Page 116  |  Page 117  |  Page 118  |  Page 119  |  Page 120  |  Page 121  |  Page 122  |  Page 123  |  Page 124  |  Page 125  |  Page 126  |  Page 127  |  Page 128  |  Page 129  |  Page 130  |  Page 131  |  Page 132